Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCR4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Soluble Ligand) | CCL17 (TARC) & CCL22 (MDC) Recombinant Proteins HEK293 expressed, high purity (>95%), endotoxin controlled. Ideal for chemotaxis and ligand-blocking assays. |
View CCL17 Products |
| Gene Delivery | CCR4 Promise-ORF / Lentivirus Full-length human CCR4 ORF for stable cell line construction. Crucial for preserving native 7-transmembrane (7-TM) conformation in cell-based assays. |
View CCR4 Products |
| Benchmark Ab | Anti-CCR4 Recombinant Antibody Biosimilar sequence based on Mogamulizumab. Recombinant positive control for FACS, ADCC, and binding assays. |
View CCR4 Products |
| Validator | CCR4 siRNA Set Target-specific knockdown verification in primary T cells or cell lines. |
View CCR4 Products |
| Related Target A | CCR8 Co-expressed on tumor-infiltrating Tregs. Essential for comparative selectivity and bispecific targeting strategies. |
View CCR8 Products |
| Related Target B | CCL22 Primary high-affinity chemokine ligand driving CCR4-mediated Treg recruitment into the tumor microenvironment. |
View CCL22 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 7-TM Conformational Integrity | Lentivirus-mediated stable cell line expression preserves native GPCR tertiary structure for binding. |
| Subfamily Off-Target Screening | Sequence-verified receptor panels (CCR1, CCR2, CCR5, CCR8) to rule out off-target cross-reactivity. |
| Lack of Controls | Clinical-grade Mogamulizumab biosimilar antibody included as a benchmark control. |
| False Positives | Validated siRNA sets included for target specificity and knockdown verification. |
Live CCR4/CD194 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCR4 therapeutics is intensifying, with major players shifting focus from traditional leukemia/lymphoma monoclonal antibodies to Treg-depleting agents in solid tumors and small-molecule antagonists. As first-generation therapies like Mogamulizumab establish clinical proof-of-concept in cutaneous T-cell lymphoma (CTCL), the next wave of R&D is targeting selective Treg depletion in the tumor microenvironment without inducing systemic autoimmunity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADCC-Enhanced mAb | Kyowa Kirin, Amgen | CTCL, T-Cell Leukemia, Solid Tumors | FACS Binding & ADCC Assays (Need CCR4 Stable Cell Lines via Lentivirus) |
| Small Molecule Antagonist | RAPT Therapeutics, Bristol Myers Squibb | Solid Tumors, Atopic Dermatitis | Ligand Competition Assays (Need High-Purity CCL17/CCL22 Recombinant Proteins) |
| Bispecific Antibody / CAR-T | Academic Institutions, Biotech Startups | Refractory Lymphomas, Solid Tumors | Selectivity Screening (Need CCR4 vs CCR8 GPCR Expression Panels) |